Alternatively, this pattern might suggest that a shift in HRAS binding preference from FHOD1 to another partner such as RALGDS is favorable for head and neck cancer but less favorable for thyroid cancer. The gene discussed is HRAS; the disease is thyroid gland carcinoma.